Supervisor, Particles, Analytical Labs NA
January 25, 2019
Key insights were obtained through survey responses from the over 300 registrants – in particular, dispelling the general perception that particle formation resultant from drug/package incompatibility or contamination is infrequent. Over half of respondents report incompatibility as an issue – a reason why packaging components must be screened early in the drug development cycle. Moreover, there appears to be no standardization on testing parameters, or use of statistical methodology for interpretation of results.
Particulate is a thrust area for West Analytical Services, LLC. Extensive experience indicates that particle levels vary based upon:
- components and interaction with drug product
- test environment
Further, this experience indicates that rigorous statistical methods are required for meaningful interpretation. To view the full recording of the webinar please click here. For more on how West can assist in addressing particle issues, contact an Account Manager or Technical Customer Support (TCS) representative.